The cranberry extract CyaniDel is produced by using a Biosfered Srl proprietary technology. It is first titrated with the BL-DMAC method to obtain the total amount of PACs and subsequently is analyzed by liquid chromatography coupled to mass spectrometry (HPLC-ESI-MS/MS) for the assessment of the content of the PAC A (and the possible presence of PAC B), and for the quantification of cyanidin and delphinidin.
A convenient and reliable source of PACs for UTI treatment
This offers several advantages:
The chemical characterization is based on the quantitative BL-DMAC method for PAC-A and the qualitative/quantitative liquid chromatography coupled to mass spectrometry analysis for the accurate identification and quantification of PACs, cyanidin and delphinidin;
The analytical methods used ensure a high quality of CyaniDel® bioactive compounds;
The precise quantification allows the exact and reliable formulation of products based on CyaniDel®;
CyaniDel® represents a convenient and reliable source of PACs for UTI treatment;
CyaniDel® contains a high content of cyanidin and delphinidin glycosides along with 5% PACs (based on BL-DMAC method).